Lantheus Holdings, Inc.
LNTHDrugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
FDA PDUFA Date Pylarify (priority)
For Prostate cancer. NDA filing. Extracted from SEC filing: 8-K
SourceFlurpiridaz F18
Coronary Artery Disease
Sestamibi
Kawasaki Disease
DEFINITY®
Cardiac Disease
DEFINITY
Cardiac Disease
Peflutren Lipid Microsphere Injectable Suspension
Liver Disease
LNTH2403 Phase 1 dose
Relapsed / Refractory Osteosarcoma
BMS747158
Ischemia
Technetium Tc99m Sestamibi
Kawasaki Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Flurpiridaz F18 | Phase 3 | Coronary Artery Disease | - | - |
Sestamibi | Phase 3 | Kawasaki Disease | - | - |
DEFINITY® | Phase 3 | Cardiac Disease | - | - |
DEFINITY | Phase 3 | Cardiac Disease | - | - |
Peflutren Lipid Microsphere Injectable Suspension | Phase 2 | Liver Disease | - | - |
LNTH2403 Phase 1 dose | Phase 2 | Relapsed / Refractory Osteosarcoma | - | - |
BMS747158 | Phase 2 | Ischemia | - | - |
Technetium Tc99m Sestamibi | Phase 2 | Kawasaki Disease | - | - |